The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Phase Ib trial of ianalumab plus ibrutinib for CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses a Phase Ib study (NCT03400176) of ianalumab, a monoclonal antibody targeting the B-cell activating factor receptor, plus ibrutinib in patients with chronic lymphocytic leukemia (CLL). The study found that ianalumab plus ibrutinib had an acceptable safety profile and showed promising preliminary activity in patients with relapsed or refractory CLL on ibrutinib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
